The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common at $0.20, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common at $0.18 and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common at $0.18.

The Series CC, DD and EE warrants are all immediately exercisable and have terms of five years, six months and nine months, respectively.

Gross proceeds should be ~$4.25M. Net proceeds will fund the development of Multikine, LEAPS and general corporate purposes.

CEL-SCI (CVM-1.8%) announces that it has submitted its response to the FDA regarding the partial clinical hold instituted in September on its Phase 3 study assessing Multikine (Leukocyte Interleukin, Injection) in patients with squamous cell carcinoma of the head and neck.

The company has not disclosed the precise nature of the agency's action but it usually involves a safety signal of some kind.

CEL-SCI Corporation (NYSEMKT:CVM) announces that it has received verbal notice from the FDA that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. The company expects to receive a formal letter within 30 days and will work diligently to address the matter. The specific reasons for the hold are not provided. The study currently has about 926 patients enrolled.

A full clinical hold means that no new patients can be recruited into the study and all dosing must cease. Patients currently enrolled can continue to be followed.

The primary endpoint of the study is overall survival over a three-year period. According to ClinicalTrials.gov, the estimated study completion date is December 2017.

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.

CEL-SCI (CVM-6.1%) founder, President & Chairman Maximilian de Clara has resigned effective immediately due to health reasons. The company says it has no current plans to appoint a new President to succeed the 87-year old Mr. de Clara.

Thinly traded nano cap CEL-SCI (NYSEMKT:CVM) eases 6% premarket on light volume in response to its announcement of an agreement with institutional investors for the direct placement of ~10M shares of common stock and five-year warrants to purchase up to ~5M shares of common at $0.55. Gross proceeds will be $5M. Closing date is August 26.

Nano cap CEL-SCI (NYSEMKT:CVM) is down 4% premarket on light volume in response to its announcement that it has entered into a definitive agreement with a single institutional investor to purchase 10M shares of common stock and warrants to purchase up to ~6.66M shares of stock, generating gross proceeds of $5M. The five-year warrants are exercisable at $0.55 per common share. Closing date is May 20.

CEL-SCI (NYSEMKT:CVM) prices its public offering of stock and warrants at $0.67 per unit which will generate up to $12M in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at $0.67 for a period of five years. Closing date is October 28.